Abstract Hereditary multiple exostoses (EXT) is an autosomal dominantly inherited disease characterized by the formation of cartilage-capped prominences (exostoses) that develop from the juxtaepiphyseal regions of the long bones. Recently, EXT1 and EXT2 genes were cloned and germline mutations of EXT1 and EXT2 were identified in EXT families. In this study, we performed a mutational analysis of EXT1 and EXT2 genes in eight unrelated Korean EXT families by polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) analysis followed by direct DNA sequencing. As a result, we were able to identify one family (SNU-OC3) with the EXT1 mutation and another family (SNU-OC15) with the EXT2 mutation. The EXT1 mutation was a 10-bp deletion at the 3Ј end of exon 5 (CTAATTTAGg) including the splice site of this exon. The EXT2 mutation identified in the SNU-OC15 family was a missense mutation at codon 85 of exon 2 (TGC AE CGC), resulting in an amino acid change from cysteine to arginine. This missense mutation cosegregated with the disease phenotype in this family, suggesting that it is the diseasecausing mutation. These two mutations identified in EXT1 and EXT2 are novel ones.
Introduction
Hereditary multiple exostoses (EXT) is an autosomal dominantly inherited disease characterized by the development of cartilage-capped exostoses (osteochondromas) from the juxtaepiphyseal regions of the long bones. Exostoses may be apparent at birth, and they are usually evident by the end of the first decade of life in 80% of individuals (Solomon, 1963) . Approximately two-thirds of the affected individuals with EXT have orthopedic complications (Wicklund et al. 1995) . But the most serious complication of EXT is malignant degeneration of benign exostoses to chondrosarcoma or to some other sarcomas (Schmale et al. 1994) .
EXT is a genetically heterogeneous disease. Linkage analysis has demonstrated that EXT is caused by at least three different genes, EXT1 on chromosome 8q23-q24 (Cooke et al. 1993) , EXT2 on chromosome 11p11-p12 (Wu et al. 1994; Wuyts et al. 1995) , and EXT3 on chromosome 19p (Le Merrer et al. 1994) . However, it now appears that most EXT families are linked to EXT1 and EXT2 loci (Halloran-Blanton et al. 1996; Raskind et al. 1998) . Recently, the EXT1 and EXT2 genes have been cloned and germline mutations of these genes confirmed in EXT families (Ahn et al. 1995; Stickens et al. 1996; Wuyts et al. 1996) . EXT1 and EXT2 show homology to each other and define a new family of related genes with putative tumor suppressor activity, as demonstrated by loss of heterozygosity in both the EXT1 region on chromosome 8 and the EXT2 region on chromosome 11 in chondrosarcomas Hecht et al. 1997) . Recent lines of evidence suggest that EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate Lind et al. 1998) .
In addition to the EXT1 and EXT2 genes, three other homologous genes belonging to the EXT gene family, EXTL1 (Wise et al. 1997) , EXTL2 (Wuyts et al. 1997) , and EXTL3 Germline mutations in the EXT1 and EXT2 genes in Korean patients with hereditary multiple exostoses homology searches with expressed sequence tags (ESTs). So far, germline mutation in EXTL genes has not been identified in EXT patients.
Since the cloning of the EXT1 and EXT2 genes, there have been a few reports describing the germline mutation screening of these genes in EXT families (Ahn et al. 1995; Hecht et al. 1997; Philippe et al. 1997; Raskind et al. 1998; Stickens et al. 1996; Wells et al. 1997; Wuyts et al. 1996; Wuyts et al. 1998) .
In this article, we report the mutation screening of EXT1 and EXT2 in eight unrelated Korean EXT families by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis followed by direct DNA sequencing.
Subjects, materials, and methods

DNA isolation from blood samples
Blood samples and clinical information on eight unrelated Korean EXT families were obtained from the Korean Hereditary Tumor Registry, at the Seoul National University College of Medicine. All families had two or more members affected with EXT. Informed consent was obtained from all patients prior to blood collection. Genomic DNA was prepared from peripheral blood, as described previously (Blin and Stafford 1976) .
Mutation screening of EXT1 and EXT2
PCR and SSCP analysis was performed for all coding sequences of the EXT1 and EXT2 genes. The primer sequences used for PCR of EXT1 and EXT2 have been described previously (Philippe et al. 1997; Wells et al. 1997) . DNA samples were PCR amplified prior to SSCP analysis under the following conditions: 94°C for 5min, followed by 35 cycles of 94°C for 30 s, 50°C-58°C for 30 s (depending on the annealing temperature for each primer pair), and 72°C for 30 s, and a final elongation step at 72°C for 5 min. Reaction mixtures in a total volume of 25 µl contained the following: 50 ng of DNA template, 0.4M each primer, 120 M each dNTP, PCR buffer (10 mM Tris, 50 mM KCl, 1.5 mM MgCl 2 , 0.001% gelatin) (Perkin Elmer Cetus, Foster City, CA, USA) 0.1 µCi/µl 32 P dCTP (3000 Ci/mmol) (Amersham, Arlington Heights, IL, USA), and Taq DNA polymerase 0.01 U/µl (Perkin Elmer Cetus). After amplification, 15 µl of the reaction mixture was diluted with 15µl of formamide dye (deionized formamide 95%, 10 mM ethylene diamine tetraacetic acid [EDTA], 0.05% xylene cyanol, and 0.05% bromphenolblue). Samples were denatured at 95°C for 4 min and placed on ice prior to loading on SSCP gel. Four µl of each reaction mixture was loaded into a 6% (48 : 1 acrylamide : bis) non-denaturing polyacrylamide gel. Electrophoresis was performed at 400 V constant voltage at 4°C for 13-16 h. Gels were dried and exposed to Fuji RX film (Fuji Photo Film, Tokyo, Japan) for 12-24 h.
DNA sequencing
When abnormal band patterns were detected by PCR-SSCP analysis, the PCR products were purified with a QIAquick PCR purification kit (Quiagen, Chatsworth, CA, USA) and sequenced directly with a Taq dideoxy terminator cyclic kit on an ABI 377 automatic DNA sequencer (Perkin-Elmer).
For mutation analysis in the EXT2 gene by direct sequencing, exons 2 and 4 of EXT2 were amplified, and the resulting PCR products were ligated into the PCRTM-II vector and subcloned, using the TA cloning system (InVitrogen, San Diego, CA, USA). Several clones were sequenced directly with a Taq dideoxy terminator cyclic kit on an ABI 377 automatic DNA sequencer (Perkin-Elmer).
The sequences were analyzed visually by comparison of the mutated sequence with a sequence from a normal control.
Results and discussion
EXT1 is composed of 11 exons and EXT2 is composed of 16 exons and the flanking intronic sequences. In this study, we searched for germline mutations of the entire coding sequences of EXT1 and EXT2, excluding exons 1a and 1b of EXT2 encoding the 5Ј-untranslated region (UTR).
In one EXT family (SNU-OC3) with EXT-affected members through four generations (Fig. 1a) , abnormal bands were detected after SSCP analysis of exon 5 of the EXT1 gene (Fig. 1b) . The proband in this family was a 15-year-old male with multiple exostoses involving the hip, knee, ankle, foot, elbow, scapula, shoulder, wrist, and hand. His father also had exostoses involving both knees. Sequencing of the exon 5 PCR product derived from the proband revealed a 10-base pair deletion at the 3Ј end of exon 5 (CTAATTTAGg), including the donor splice site of intron 5 (Fig. 1c) . The same mutation was also identified in the proband's father, confirming that this mutation cosegregated with the EXT phenotype in this family. We did not perform a detailed analysis of the consequences of this mutation. But since the mutation involves the conserved GT splicing junction at the 5Ј end of intron 5, the mutation would result in improper splicing of this exon. The consequences of this mutation could possibly be intron 5 retention or exon 5 skipping, joining exon 4 to exon 6, or use of the cryptic 5Ј splice site. In either case, the most likely result would be premature translation termination, producing a truncated protein.
In the EXT2 gene, PCR-SSCP analysis did not reveal any abnormal band. This could be due to the limited sensitivity of SSCP, considering the fact that the sizes of the PCR products of EXT2 varied from 253bp to 442 bp. So, we directly sequenced exons 2 and 4 of EXT2, because EXT2 mutations are more fequent in these exons . As a result, we were able to identify a missense mutation in the SNU-OC15 family (Fig. 2a,b) . In this family, the proband was a 5-year-old boy with exostoses on both legs (femur, tibia), both arms (radius, ulna, humerus), and both feet (proximal phalanges). His mother also had exostoses in both knees. Sequence analysis showed that the proband had a germline missense mutation (TGC AE CGC) at codon 85 of the EXT2 gene, leading to a cysteine-toarginine substitution. The same missense mutation was identified in the proband's mother. To confirm that the identified mutation was the disease-causing one, we sequenced exon 2 of EXT2 from six normal (without exostoses phenotype) family members, including the younger sister of the proband and three maternal aunts and two uncles. In the rest of the family members, the mutation b Sequence analysis of exon 2 of EXT2 revealed a missense mutation at codon 85 (TGC AE CGC), resulting in a cysteine-to-arginine substitution. This missense mutation cosegregated with the disease phenotype in this family, suggesting that this mutation is the cause of EXT identified in the proband and his mother could not be identified. Thus, the missense mutation identified cosegregated with the exostoses phenotype, suggesting that the mutation is the disease-causing one. Direct sequencing of 100 control chromosomes from unrelated and unaffected normal individuals did not reveal this missense mutation, thus excluding the possibility of a rare polymorphism, Analysis of EXT pedigrees has revealed that most are associated with EXT1 and EXT2 (Halloran-Blanton et al. 1996; Raskind et al. 1998) , with EXT3 probably playing only a minor role. Our results provide further support for EXT1 and EXT2 genes being involved in EXT.
There have been 35 different EXT1 mutations described in 43 families, and 12 different EXT2 mutations described in 16 families Raskind et al. 1998 ). All of these mutations have been found in families from Western countries. Seventy-seven percent of the mutations identified in the EXT1 gene are nonsense mutations, splice-site mutations, or frameshift mutations, which cause premature termination of the EXT1 protein . The consequence of the mutation identified in our SNU-OC15 family (10-base pair deletion at the 3Ј end of exon 5, including the splice donor site of intron 5) is unknown. But since the deletion involves the conserved GT splicing junction at the 5Ј end of intron 5, it is likely that the mutation would result in improper splicing of this exon with production of a truncated EXT1 protein. However, there is also a possibility that the mutation may result in a frameshift.
Of the 12 EXT2 mutations reported thus far , 11 are nonsense mutations, splice-site mutations, or frameshift mutations, which cause premature termination of EXT2 protein ). There has only been one missense mutation, described in two families at exon 4 of the EXT2 gene (Philippe et al. 1997) . The missense mutation identified in our family (SNU-OC15) was at codon 85 of exon 2 of the EXT2 gene, with a resultant amino acid change from cysteine to arginine. Since this mutation cosegregated with the EXT phenotype in this family and since the same mutation was not identified in 100 chromosomes from an unrelated unaffected normal population, there is a high likelihood that this mutation is the disease-causing one. If this is the case, codon 85 of EXT2 may be an important domain for the proper function of the EXT2 protein.
The mutations identified in the EXT1 and EXT2 genes from our EXT families are novel ones, and extend the germline mutation spectrum identified in EXT.
